Corporate Profile

From April 1986 to September 2023, I worked for a Japan-based global pharmaceutical company for 31 years and for a US-based global CRO for 6.5 years, most of which time was spent in drug clinical development in Japan and Asia.

We founded t2T Healthcare Inc. in October 2023 so that we can contribute more flexibly and directly to many companies and organizations using our experience, know-how and network in drug development/regulatory affairs/sales & marketing, which we have cultivated.

This foundation is an extension of the web magazine “Drug R&D Expert” which was launched jointly with Japanese and Chinese colleagues in July 2021.  For example, Japan and China are neighbors in Asia, and both are leading players in the pharmaceutical R&D and market, but in talking with friends from both countries, we feel that there are actually many things that Japan and China seem to know about each other but do not.

We hope that our experience, know-how, and network will reduce the barriers between China, other Asian countries, Europe and the United States, and Japan, and that we can serve as a bridge for people around the world to trust each other and work together smoothly.

We desire to help patients in countries and regions around the world who are waiting for new medicines in any way we can.

Tetsuomi Takano
President and CEO, t2T Healthcare Inc.

Company Namet2T Healthcare Inc.
Mailing Address6-36-1302, Shinogawamachi, Shinjuku-ku, Tokyo 162-0814, Japan
Registered Head Office1-26-19-405, Shinkoiwa, Katsushika-ku, Tokyo 124-0024, Japan
Date of FoundationOctober 25th, 2023
Capital5 million JPY
Representative Director Tetsuomi Takano (President and Chief Executive Officer)
Bank of AccountHead Office, Sumitomo Mitsui Banking Corporation
End of Accounting PeriodSeptember
Business Description
  1. Technical support services, various surveys, provision of information, consultancy, referral services, and outsourcing contracting and brokerage services in relation to “Research and development work for pharmaceuticals and other products, consultation with regulatory authorities, preparation and submission of investigational new drugs (INDs) and new drug applications (NDAs), etc., clinical trials, licensing, and outsourcing of such work“
  2. Collection and provision of information on the economies, cultures and lifestyles of countries around the world as well as consultancy, referral services, and outsourcing contracting and brokerage services to support the overseas operations of Japanese companies
  3. Consultancy, referral services, and outsourcing contracting and brokerage services to support foreign companies entering the Japanese market
Affiliated OrganizationKansai Pharmaceutical Industries Association (KPIA)
PAGE TOP